Q2 2016 · —
Revenue$381.16M$381.16M +14.2% vs Q2 2015+13.4% vs Q1 2016
Net Income$114.50M$114.50M +29.9% vs Q2 2015+51.0% vs Q1 2016
EPS Diluted$1.85$1.85 +32.1% vs Q2 2015+52.9% vs Q1 2016
Gross Profit$355,130,000+14.4%
Operating Income$168,735,000+10.1%
Operating Cash Flowderived$127,014,000−9.6%
Free Cash Flowderived$123,458,000−3.2%
Margins · derived
Gross margin93.2%+0.2 pt vs Q2 2015
Operating margin44.3%−1.7 pt vs Q2 2015
Net margin30.0%+3.6 pt vs Q2 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2016 | Q2 2015 | Q2 2014 | Q2 2013 |
|---|---|---|---|---|
| Revenue | $381.16M | $333.75M | $291.23M | $208.25M |
| Net Income | $114.50M | $88.11M | $43.66M | $42.19M |
| EPS Diluted | $1.85 | $1.40 | $0.70 | $0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR